Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer

<table>Comparison of patient disease-free survival rates. In patients receiving GEM treatment after surgery (<svg height="10.9125" id="M14" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 42.912498 10.9125" width="42.912498" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="27.969212" y="0">3</tspan>
</text>
</g>
</g>
</svg>), disease-free survival was compared according to percent of thymidylate synthase (TS) protein expression. Months after surgery; mean ± SD.</table>

International Scholarly Research Notices

fig3

Figure 3

Figure 3: Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer 